Showing posts with label Promising. Show all posts
Showing posts with label Promising. Show all posts

Saturday, August 19, 2017

Tapentadol A Promising Option For Neuropathic Pain


Today's post from diabetesincontrol.com (see link below) talks about Tapentadol (Nucynta) being effective for diabetes-related neuropathy pain. Earlier articles on this blog (see alphabetical list to the right) have highlighted its efficacy for HIV-related neuropathy and other neuropathies also fall under its benefits (but as yet not approved for all). So why isn't this breakthrough semi-opiate ending up as a front-line treatment? The answer seems to lie in the cost and the competition between drug companies, which disregards the needs of the patients, who have been looking for an efficient chronic pain management drug with less side effects than its competitors. The FDA has approved it, which is the first major step with any new drug but doctors throughout the western world are possibly being pressured into not prescribing it due to pressure from health insurance companies who are always looking for cheaper options. It's symptomatic of a culture where economic cuts are paramount and the power of established drug company lobbies has never been stronger. However, if Tapentadol really is a better option for many patients living with neuropathy, then denying them access is at the very least, morally questionable.


Tapentadol-ER for the Treatment of Diabetes Associated Peripheral Neuropathy (DPN)

 This article originally posted 26 June, 2014 and appeared in Medication, Neuropathy, Pain, Issue 735

The FDA recently approved tapentadol-ER (Nucynta ER) for the treatment of peripheral neuropathy in diabetics.... 

Advertisement
With an increasing number of patients being diagnosed with diabetes, complications associated with the disease are becoming more common. 

Diabetic peripheral neuropathy (DPN) is the most common neuropathic pain seen in patients with diabetes, affecting up to 50% of patients. It is characterized as a burning or tingling sensation that affects the lower limbs. Painful DPN is associated with increased morbidity, mortality and substantial costs to the healthcare system.

Tapentadol-ER is a schedule II opioid analgesic that is commonly used for the treatment of moderate to severe chronic pain. It is unique in its dual acting mechanism in which it works as both a weak mu-opioid receptor agonist and a norepinephrine-reuptake inhibitor.

This distinct mechanism is said to represent a new pharmacological class of medications: MOR-NRI. Tapentadol ER is a weak mu-opioid receptor agonist, having an 18 fold decrease in receptor affinity when compared to morphine. Despite this decrease in affinity, tapentadol ER only produces a two to three fold decrease in analgesic effects when studied in animals. It also acts on the alpha-2 receptor located on the noxious nerve fibers in the spinal cord and throughout the central nervous system, inhibiting transmission of pain impulses. The dual acting mechanism of tapentadol-ER works to control the complex pathology that is neuropathic pain.

Until this approval the only options for FDA approved medications to treat diabetic peripheral neuropathy (DPN) were pregabalin and duloxetine.
Tapentadol ER provides sufficient pain relief with convenient twice daily dosing. The starting dose for opioid-naïve patients is 50mg twice daily and can be titrated to an effective dose of 100mg to 250mg twice daily. The maximum daily dose is 250mg twice daily. The maximum serum concentration is increased by 17% when taken in combination with a high fat breakfast but according to package labeling may be administered without regards to food.

Tapentadol-ER undergoes extensive hepatic metabolism and therefore must be adjusted in patients with hepatic impairment. The usual adjustment is extension of administration duration to once every 24 hours in patients with mild to moderate hepatic impairment (Child-Pugh Score of 7 to 9). It is contraindicated in patients with severe hepatic impairment. Tapentadol ER and its metabolites are excreted by the kidneys; however, no dose adjustments are required for patients with renal impairment.

The efficacy and safety of tapentadol ER has been studied in two DPN studies. Both studies were placebo controlled randomized studies in which patients had either type 1 or type 2 diabetes and painful DPN for a period of at least six months. Pain intensity was at least a 5 on an 11 point scale. In both studies approximately two-thirds of participants were opioid-naïve. Both studies came to the conclusion that tapentadol ER provided statistically significant improvement of pain intensity as compared to that of placebo.

Treatment related adverse effects were reported at 70.9% for those taking tapentadol ER and 51.8% for those taking placebo. The most common side effects were nausea, diarrhea, anxiety and dizziness. Most were mild to moderate and did not lead to discontinuation of the medication.
Practice Pearls:
  • The incidence of diabetes is on the rise as is the complication of neuropathy
  • The FDA approval of tapentadol ER for treatment of diabetic peripheral neuropathy provides practitioners an additional therapeutic option with a convenient twice daily dosing regimen.
  • Tapentadol ER has a unique dual mechanism suggesting that it may be particularly useful for complex pain associated with DPN.
Consult Pharm. 2013 Oct;28(10):672-5. doi: 10.4140/TCP.n.2013.672
Comment from Dr. Aaron Vinik, Diabetes In Control Advisory Board member, and study author:

Pain associated with DPN is a common complication of diabetes affecting 10-26% of patients for which the only approved drugs are Pregabalin and Duloxetine which at best reduce pain by 30% in about half the patients treated leaving a significant portion of the affected population without resort to significant pain relief. A paradox here is that third party payors insist that less expensive drugs such as the tricyclics should be used as first line despite the fact that they have cardiovascular cautions as well as not paying heed to the need for attention to the comorbidities of sleep loss, depression and anxiety as determinants of choice of initial therapies. However, the problem occurs when first line therapies have failed and the need for greater reduction of pain arises wherein a combination of drugs acting through different parts of the pain pathway have proved useful. The problem with this approach is that this increases the burden of drugs patients with diabetes must take with untoward effects, particularly cognitive impairment, which can have a disastrous impact on decision-making and is the cause of induced hypoglycemia and its consequences. Tapendalol represents a proposed new class of centrally acting analgesics combining two mechanisms of action: u-opiod receptor agonism and norepinephrine reuptake inhibition. Tapentadol extended release has been shown to be effective and well-tolerated for the management of severe, chronic pain in randomized, double blind, placebo-controlled and/or active comparator controlled phase 3 studies. Two studies (of which I am first author and coauthor of the second) were designed using a randomized withdrawal multicenter placebo control design and reached their primary endpoint and in August 2012 tapentadol ER received FDA approval for the mangement of pain associated with DPN in adults when a continuous around the clock opiod analgesic was needed for an extended period of time. To determine if subgroups would benefit, the data from the two studies were pooled. The results of this pooled analysis indicated that tapentadol ER is effective and well-tolerated for the management of neuropathic pain associated with DPN, improved measures of health related quality of life and had constent efficacy across different patient subgroups divided by age, gender, race, opiod experience and pain intensity. Sensitivity analyses showed that in the tepentadol arm ( n=360) compared with placebo ( n=342) the drug 54% achieved >30% pain reduction and 38.9%;50% pain reduction and the significant side effects were nausea, vomiting, dizziness, and somnolence. These figures argue in favor of using the drug as a second or third tier drug with the recognition that its effects are modest and there is the potential for habituation. Ultimately, what is needed is a drug that will reverse the pathogenic process and that the need for pain-relieving drugs will be the bandaid to be used in the interval before the damage to the nervous system has been resolved. 

http://www.diabetesincontrol.com/articles/diabetes-news/16529-tapentadol-er-for-the-treatment-of-diabetes-associated-peripheral-neuropathy-dpn

Friday, July 14, 2017

Omega 3 Fatty Acids Promising For Nerve Damage


Today's post from sciencedaily.com (see link below) reinforces the information provided in a post from 2 days ago on this blog and that is that fish oil, reinforced with Omega 3 fatty acids may well be of great benefit to damaged nerves. It has been found that one type of omega 3 fatty acid called resolvins, can restore nerve health in mice. Now we're pretty familiar with studies carried out on long-suffering rodents and can become blasé about yet more potential benefits that haven't been proved in humans. They generally mean that whatever the latest finding may be, it will be years before it reaches our doctor's prescription pad but in this case, taking fish oil supplements to compensate our lack of fish in our diets may not be such a bad idea anyway - if they can also improve our nerve problems in the meantime, until the science proves it beyond doubt, then it's pretty much a win-win situation.


Fish oil may help with diabetic neuropathy
Source:American Physiological Society Date:May 6, 2015 

(APS)Summary:

Approximately 50 percent of patients with diabetes suffer from nerve damage, or neuropathy. No cure exists, and the most effective treatment, keeping blood sugar in control, only slows neuropathy. A new study, however, introduces a new alternative, omega-3 fatty acids found in fish oil. The study shows that fish oil supplements can restore the condition of nerves damaged from diabetes in mice.

"Diabetic neuropathy is a very costly and debilitating complication of diabetes. It is the leading cause of foot ulcers and non-trauma-related amputations, and the impact of diabetic neuropathy on the patient and family are unmeasurable," said Mark Yorek of the VA Medical Center in Iowa City, the study's lead investigator. Fish oil is an attractive treatment approach because "supplements are considered very safe and could be easily translated into everyday care. Fish oil would be easy to take, like a vitamin, and should have few side effects when combined with other medications," explained Yorek.

Previous studies of obesity and diabetes have reported better blood sugar handling, liver function and reduced inflammation with omega-3 fatty acids treatment. The health benefits were attributed to protective molecules produced from omega-3 fatty acids, including one type called resolvins. The research group had previously observed that diets enriched with omega-3 fatty acids from fish oil improved diabetic neuropathy in rats with Type 1 and Type 2 diabetes, and in this new study they examined why.

Researchers used a mouse model of diabetes to study the effect of fish oil. Diabetic mice were fed a high-fat diet and treated with daily injections of resolvin or given a high-fat diet in which half the fat came from fish oil. The results were compared to healthy, non-diabetic mice.

The researchers found that untreated diabetic mice had diminished sense of touch in their paws that corresponded to fewer nerves in the paw's skin and slower transmission of signals along the nerves. The eyes of untreated diabetic mice also had fewer nerves. Though dietary fish oil and resolvin did not lower glucose levels closer to healthy range, they improved nerve health in terms of density and sensory signal transmission. The researchers also observed that resolvin stimulated nerve cells to grow.

"Even though a lot more work needs to be done, including clinical trials with human subjects, our animal studies suggest that fish oil can reverse some of the harmful effects of diabetes on the nerves. Our intent is to do more animal studies to demonstrate that fish oil treatment can reverse the harmful effects of diabetes on nerves even after a long period of poorly controlled diabetes. After completion of this work, we hope to begin studies with diabetic patients with neuropathy," Yorek said.

Story Source:


The above story is based on materials provided by American Physiological Society (APS). Note: Materials may be edited for content and length.

Journal Reference:

Hanna Shevalye, Matthew S Yorek, Lawrence J Coppey, Amey Holmes, Matthew M Harper, Randy H Kardon, Mark A. Yorek. Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes. Journal of Neurophysiology, 2015; jn.00224.2015 DOI: 10.1152/jn.00224.2015


http://www.sciencedaily.com/releases/2015/05/150506182713.htm